Characteristics of patients at baseline
| Placebo(n = 12) | Fluticasone(n = 18) | Montelukast(n = 19) | p value | |
|---|---|---|---|---|
| Data are expressed as mean (SD). | ||||
| BD, bronchodilator; FEV1, forced expiratory volume in 1 second; SVC, vital capacity | ||||
| Atopic means one or more positive allergy skin prick test, n indicates the number of atopic subjects. | ||||
| *Symptoms score ranged from 5 (very great deal of discomfort or distress) to 35 (no discomfort or distress); see Methods. | ||||
| FEV1 predicted values from Crapo et al28 and are pre-bronchodilator. | ||||
| **Geometric mean (geometric SD). | ||||
| Age (years) | 38.8 (12.2) | 35.4 (13.9) | 31.4 (9.9) | 0.3 |
| Sex (no male) | 4 | 8 | 8 | 0.8 |
| Smoking (current/ex) | 2/0 | 0/5 | 3/2 | 0.6 |
| Atopic (n) | 10 | 16 | 16 | 0.9 |
| Symptoms score* | 22.5 (4.5) | 23.2 (6.4) | 25.6 (5.5) | 0.3 |
| Salbutamol (puffs/day) | 2.6 (1.9) | 3.3 (2.6) | 3.3 (3.1) | 0.8 |
| Pre BD FEV1 (% pred) | 80.3 (22.5) | 72.0 (16.0) | 76.7 (15.9) | 0.4 |
| Pre BD FEV1/SVC (%) | 67.1 (15.2) | 67.1 (12.2) | 67.9 (9.2) | 1.0 |
| Change in FEV1 after BD (%) | 20.2 (15.9) | 18.1 (15.6) | 18.5 (9.6) | 0.9 |
| Sputum eosinophils (%)** | 15.4 (2.4) | 11.9 (2.3) | 10.7 (2.3) | 0.1 |